241 related articles for article (PubMed ID: 21824073)
21. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi.
de Castro SL
Acta Trop; 1993 Apr; 53(2):83-98. PubMed ID: 8098901
[TBL] [Abstract][Full Text] [Related]
22. Novel cruzain inhibitors for the treatment of Chagas' disease.
Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
[TBL] [Abstract][Full Text] [Related]
23. A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors.
Maluf FV; Andricopulo AD; Oliva G; Guido RV
Future Med Chem; 2013 Nov; 5(17):2019-35. PubMed ID: 24215344
[TBL] [Abstract][Full Text] [Related]
24. Approaches for the development of new anti-Trypanosoma cruzi agents.
Moreira DR; Leite AC; dos Santos RR; Soares MB
Curr Drug Targets; 2009 Mar; 10(3):212-31. PubMed ID: 19275558
[TBL] [Abstract][Full Text] [Related]
25. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
[TBL] [Abstract][Full Text] [Related]
26. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host.
Maya JD; Cassels BK; Iturriaga-Vásquez P; Ferreira J; Faúndez M; Galanti N; Ferreira A; Morello A
Comp Biochem Physiol A Mol Integr Physiol; 2007 Apr; 146(4):601-20. PubMed ID: 16626984
[TBL] [Abstract][Full Text] [Related]
27. Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease.
Cazzulo JJ
Curr Top Med Chem; 2002 Nov; 2(11):1261-71. PubMed ID: 12171584
[TBL] [Abstract][Full Text] [Related]
28. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy of Chagas' disease: status and new developments.
Cerecetto H; González M
Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
[TBL] [Abstract][Full Text] [Related]
30. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
Urbina JA
J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
[TBL] [Abstract][Full Text] [Related]
31. Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds.
Cerecetto H; González M
Mini Rev Med Chem; 2008 Nov; 8(13):1355-83. PubMed ID: 18991753
[TBL] [Abstract][Full Text] [Related]
32. Zoledronate repositioning as a potential trypanocidal drug. Trypanosoma cruzi HPRT an alternative target to be considered.
Valsecchi WM; Delfino JM; Santos J; Fernández Villamil SH
Biochem Pharmacol; 2021 Jun; 188():114524. PubMed ID: 33741333
[TBL] [Abstract][Full Text] [Related]
33. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
Benaim G; Sanders JM; Garcia-Marchán Y; Colina C; Lira R; Caldera AR; Payares G; Sanoja C; Burgos JM; Leon-Rossell A; Concepcion JL; Schijman AG; Levin M; Oldfield E; Urbina JA
J Med Chem; 2006 Feb; 49(3):892-9. PubMed ID: 16451055
[TBL] [Abstract][Full Text] [Related]
34. Polypharmacology in the Treatment of Chagas Disease.
Aguilera E; Alvarez G; Cerecetto H; González M
Curr Med Chem; 2019; 26(23):4476-4489. PubMed ID: 29637852
[TBL] [Abstract][Full Text] [Related]
35. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease.
Haupt VJ; Aguilar Uvalle JE; Salentin S; Daminelli S; Leonhardt F; Konc J; Schroeder M
Curr Pharm Des; 2016; 22(21):3124-34. PubMed ID: 26873186
[TBL] [Abstract][Full Text] [Related]
36. The ubiquinone synthesis pathway is a promising drug target for Chagas disease.
Nara T; Nakagawa Y; Tsuganezawa K; Yuki H; Sekimata K; Koyama H; Ogawa N; Honma T; Shirouzu M; Fukami T; Matsuo Y; Inaoka DK; Kita K; Tanaka A
PLoS One; 2021; 16(2):e0243855. PubMed ID: 33539347
[TBL] [Abstract][Full Text] [Related]
37. Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi.
Freymann DM; Wenck MA; Engel JC; Feng J; Focia PJ; Eakin AE; Craig SP
Chem Biol; 2000 Dec; 7(12):957-68. PubMed ID: 11137818
[TBL] [Abstract][Full Text] [Related]
38. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
[TBL] [Abstract][Full Text] [Related]
39. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Engel JC; Ang KK; Chen S; Arkin MR; McKerrow JH; Doyle PS
Antimicrob Agents Chemother; 2010 Aug; 54(8):3326-34. PubMed ID: 20547819
[TBL] [Abstract][Full Text] [Related]
40. Trypanosoma cruzi Invasion into Host Cells: A Complex Molecular Targets Interplay.
Campo VL; Martins-Teixeira MB; Carvalho I
Mini Rev Med Chem; 2016; 16(13):1084-97. PubMed ID: 27281167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
